STOCKS | CSPC Pharma Starts Phase I Trial Of SYH2056 For Depression

CSPC Pharmaceutical Group (01093) said its SYH2056 tablet, which is being developed for the treatment of depression, has begun a Phase I clinical trial in China, according to ETNet. The study, protocol number SYH2056-001, will assess the safety, tolerability and pharmacokinetic characteristics of a single oral dose in healthy Chinese participants, as well as the effect of food.